Next Article in Journal
Domain IV of Annexin A5 Is Critical for Binding Calcium and Guarantees Its Maximum Binding to the Phosphatidylserine Membrane
Next Article in Special Issue
Novel Mixed-Type Inhibitors of Protein Tyrosine Phosphatase 1B. Kinetic and Computational Studies
Previous Article in Journal
A DNA Barcode-Based RPA Assay (BAR-RPA) for Rapid Identification of the Dry Root of Ficus hirta (Wuzhimaotao)

Vanadium Compounds as PTP Inhibitors

Developmental Biology and Cancer Programme, UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK
Author to whom correspondence should be addressed.
Molecules 2017, 22(12), 2269;
Received: 30 November 2017 / Revised: 14 December 2017 / Accepted: 15 December 2017 / Published: 19 December 2017
(This article belongs to the Special Issue Protein-Tyrosine Phosphatase Inhibitors)
Phosphotyrosine signaling is regulated by the opposing actions of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs). Here we discuss the potential of vanadium derivatives as PTP enzyme inhibitors and metallotherapeutics. We describe how vanadate in the V oxidized state is thought to inhibit PTPs, thus acting as a pan-inhibitor of this enzyme superfamily. We discuss recent developments in the biological and biochemical actions of more complex vanadium derivatives, including decavanadate and in particular the growing number of oxidovanadium compounds with organic ligands. Pre-clinical studies involving these compounds are discussed in the anti-diabetic and anti-cancer contexts. Although in many cases PTP inhibition has been implicated, it is also clear that many such compounds have further biochemical effects in cells. There also remain concerns surrounding off-target toxicities and long-term use of vanadium compounds in vivo in humans, hindering their progress through clinical trials. Despite these current misgivings, interest in these chemicals continues and many believe they could still have therapeutic potential. If so, we argue that this field would benefit from greater focus on improving the delivery and tissue targeting of vanadium compounds in order to minimize off-target toxicities. This may then harness their full therapeutic potential. View Full-Text
Keywords: protein tyrosine phosphatases; PTP; vanadium; oxidovanadium; oxovanadium; vanadate; BMOV; diabetes; cancer protein tyrosine phosphatases; PTP; vanadium; oxidovanadium; oxovanadium; vanadate; BMOV; diabetes; cancer
Show Figures

Figure 1

MDPI and ACS Style

Irving, E.; Stoker, A.W. Vanadium Compounds as PTP Inhibitors. Molecules 2017, 22, 2269.

AMA Style

Irving E, Stoker AW. Vanadium Compounds as PTP Inhibitors. Molecules. 2017; 22(12):2269.

Chicago/Turabian Style

Irving, Elsa, and Andrew W. Stoker. 2017. "Vanadium Compounds as PTP Inhibitors" Molecules 22, no. 12: 2269.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop